BioTheryX is a clinical-stage biopharmaceutical company based in San Diego focused on targeted protein degradation and multi-kinase inhibition to develop cancer treatments. Its principal platform centers on PHM "molecular glues" that harness the body's protein disposal system to selectively degrade disease-causing proteins, alongside PHM-based PROTACs and monovalent degraders. Lead programs include molecular glue BTX-1188, expected to enter the clinic by the end of 2021, and multi-kinase inhibitor BTX-A51, which is in Phase 1 with planned expansion into solid tumors and indications including acute myeloid leukemia and myelodysplastic syndromes. The company intends to use proceeds from a $92M Series E to advance multiple protein degradation programs toward IND-enabling studies and clinical development. Additional degradation programs are on track for IND-enabling activities in 2022. BioTheryX positions its platform as potentially applicable to targets previously considered undruggable and is initially focused on oncology indications with high unmet need. BioTheryX is a clinical-stage biopharmaceutical company based in San Diego focused on restoring protein homeostasis via targeted protein degradation, PHM® molecular glues, PHM®-based PROTACs and multi-kinase inhibition. Its principal technology platform is designed to use the body’s protein disposal system to selectively degrade and remove disease-causing proteins and to regulate protein equilibrium with small molecules. The company is advancing BTX-A51 in a Phase 1 clinical trial and has a pre-clinical pipeline of therapeutic candidates that leverage its PHM platforms. BioTheryX intends to use the new funding to accelerate the BTX-A51 Phase 1 timeline by adding clinical sites beyond Memorial Sloan-Kettering Cancer Center and to continue IND-enabling studies for PHM and PHM-based PROTAC candidates. The company will also use proceeds for general corporate development and to speed development of its pre-clinical programs. David Stirling, Ph.D., serves as Chairman and CEO.

Total raised

$127M

Funding rounds

2

Latest round

Series E

Latest activity

May 2021